Y Intercept Hong Kong Ltd Acquires 954,072 Shares of Upstream Bio, Inc. $UPB

Y Intercept Hong Kong Ltd grew its holdings in Upstream Bio, Inc. (NASDAQ:UPB) by 2,049.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,000,631 shares of the company’s stock after acquiring an additional 954,072 shares during the period. Y Intercept Hong Kong Ltd owned about 1.84% of Upstream Bio worth $9,006,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Upstream Bio during the fourth quarter worth about $78,264,000. UBS Group AG lifted its holdings in Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after purchasing an additional 1,533,972 shares in the last quarter. Janus Henderson Group PLC bought a new position in Upstream Bio in the 4th quarter worth approximately $41,423,000. Pictet Asset Management Holding SA bought a new position in Upstream Bio in the 4th quarter worth approximately $20,991,000. Finally, Vestal Point Capital LP purchased a new stake in Upstream Bio during the 4th quarter valued at approximately $19,548,000.

Analysts Set New Price Targets

UPB has been the topic of several research analyst reports. Mizuho lowered their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. JPMorgan Chase & Co. cut shares of Upstream Bio from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $8.00 in a research note on Friday, June 12th. Evercore downgraded shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a report on Friday, March 27th. Weiss Ratings lowered Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Finally, HC Wainwright started coverage on Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 target price on the stock. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Upstream Bio currently has a consensus rating of “Hold” and an average target price of $33.17.

Upstream Bio Price Performance

Shares of NASDAQ:UPB opened at $7.51 on Friday. The firm has a fifty day simple moving average of $7.79 and a two-hundred day simple moving average of $14.62. Upstream Bio, Inc. has a 52 week low of $5.85 and a 52 week high of $33.68. The stock has a market capitalization of $408.69 million, a P/E ratio of -2.58 and a beta of 1.23.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The business had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.03 million. On average, analysts expect that Upstream Bio, Inc. will post -2.9 earnings per share for the current year.

Upstream Bio Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.